Asarfi Hospital

Which are the latest news on Asarfi Hospital?

Why is Asarfi Hospital Ltd falling/rising?

As of 05-Sep, Asarfi Hospital Ltd's stock price is rising to 196.70, reversing a three-day decline and outperforming its sector by 2.33%. Increased investor participation and a position above the 200-day moving average suggest positive momentum despite recent declines.

As of 05-Sep, Asarfi Hospital Ltd's stock price is rising, currently at 196.70, with a change of 0.3 (0.15%) upward. This increase follows a trend reversal, as the stock has gained after three consecutive days of decline. Additionally, the stock has outperformed its sector by 2.33% today, indicating positive momentum. <BR><BR>Investor participation has also increased, with delivery volume rising by 11.11% against the 5-day average, suggesting growing interest in the stock. Furthermore, while the stock is currently lower than the 5-day, 20-day, 50-day, and 100-day moving averages, it remains above the 200-day moving average, which can be a positive sign for investors. <BR><BR>Overall, these factors contribute to the stock's upward movement, despite its recent performance over the past week and month showing declines relative to the benchmark Sensex.

Who are in the management team of Asarfi Hospital?

The management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer).

The management team of Asarfi Hospital includes the following individuals:<BR><BR>1. Udai Pratap Singh - Managing Director<BR>2. Madhuri Singh - Executive Director<BR>3. Sukanti Kumar Das - Director<BR>4. Amit Kumar Barnwal - Independent Director<BR>5. Rajkumari Sharma - Independent Director<BR>6. Seepika Gupta - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about Asarfi Hospital or its operations, feel free to ask!

What does Asarfi Hospital do?

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of June 2026, it reported net sales of 48 Cr and a net profit of 4 Cr, with a market cap of INR 418 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 48 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 418 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 17.48% <BR>Price-to-Book: 4.13 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Asarfi Hospital?

Asarfi Hospital's peers include Shalby, GPT Healthcare, Lotus Eye Hospital, Aashka Hospitals, Chandan Healthcare, Unihealth Hospital, Aprameya Engineering, and Vaidya Sane. Asarfi Hospital has a good management risk rating and the highest 1-year return at 77.75%, outperforming its peers.

Peers: The peers of Asarfi Hospital are Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, Chandan Healthca, Unihealth Hosp, Aprameya Enginee, and Vaidya Sane.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Aprameya Enginee, while Good management risk is found at Asarfi Hospital, Chandan Healthca, and Unihealth Hosp. Average management risk is noted at Shalby, while Below Average management risk is present at Lotus Eye Hospit, Aashka Hospitals, and Vaidya Sane, and the rest. Growth is Excellent at Chandan Healthca and Unihealth Hosp, Good at Asarfi Hospital, while Below Average growth is seen at Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, and the rest. Capital Structure is Excellent at GPT Healthcare and Unihealth Hosp, Good at Asarfi Hospital, Shalby, and Aprameya Enginee, while Average capital structure is noted at Aashka Hospitals and Below Average at Lotus Eye Hospit and Vaidya Sane.<BR><BR>Return Snapshot: Asarfi Hospital has the highest 1-year return at 77.75%, while Lotus Eye Hospit has the lowest at -6.51%. Compared to its peers, Asarfi Hospital's return significantly outperforms the others. Additionally, Chandan Healthca, Unihealth Hosp, Aprameya Enginee, and Vaidya Sane all reported a six-month return of 0.00%.

How big is Asarfi Hospital?

As of 31st August, Asarfi Hospital Ltd has a market capitalization of 418.00 Cr, with recent Net Sales of 183.76 Cr and a Net Profit of 17.81 Cr. The latest balance sheet shows Shareholder's Funds of 80.98 Cr and Total Assets of 163.89 Cr.

As of 31st August, Asarfi Hospital Ltd has a market capitalization of 418.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Asarfi Hospital reported Net Sales of 183.76 Cr and a Net Profit of 17.81 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 80.98 Cr and Total Assets of 163.89 Cr.

Should I buy, sell or hold Asarfi Hospital Ltd?

Are Asarfi Hospital Ltd latest results good or bad?

Asarfi Hospital Ltd's latest results show mixed performance: while net profit increased 9.19% year-on-year, it fell 27.68% quarter-on-quarter, and revenue grew 28.89% year-on-year but slightly declined 1.87% from the previous quarter. The drop in profitability margins has raised concerns, leading to a negative market reaction.

Asarfi Hospital Ltd's latest results present a mixed picture. In the fourth quarter of FY26, the company reported a net profit of ₹3.92 crore, which is a significant decline of 27.68% compared to the previous quarter. However, on a year-on-year basis, net profit increased by 9.19%. <BR><BR>Revenue for the same quarter was ₹45.24 crore, reflecting a slight decrease of 1.87% from the previous quarter but a robust increase of 28.89% year-on-year. While the top-line growth is encouraging, the decline in profitability metrics raises concerns. The operating margin fell sharply to 17.06%, down from 21.93% in the previous quarter, and the PAT margin also decreased to 8.66%, down from 11.76%. <BR><BR>Overall, while the revenue growth year-on-year is positive, the sequential decline in both net profit and operating margins indicates operational challenges that the company needs to address. This has led to a negative market reaction, with the stock experiencing a significant drop in value following the results. Investors may want to consider these factors carefully when evaluating the company's performance.

When is the next results date for Asarfi Hospital Ltd?

The next results date for Asarfi Hospital Ltd is 07 August 2026.

The next results date for Asarfi Hospital Ltd is scheduled for 07 August 2026.

Is Asarfi Hospital overvalued or undervalued?

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

How has been the historical performance of Asarfi Hospital?

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

Who are the top shareholders of the Asarfi Hospital?

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

What is the technical trend for Asarfi Hospital?

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

Has Asarfi Hospital declared dividend?

No Dividend History Available